Company / Revenue per Share
Acadia Pharmaceuticals Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$6.43
FY2025
5-year range
$3.03 / $6.43
FY2021-FY2025
Trend
+10.5%
vs FY2024
Sector context
#60 of 154
Health Care
What the data says
At $6.43, Acadia Pharmaceuticals's revenue per share ranks #60 of 154 in the Health Care sector. Revenue per Share has increased for 9 consecutive years, from $0.17 in FY2016 to $6.43 in FY2025.
Based on SEC 10-K filings.
6.43 in FY2025 with a 5-year CAGR of +17.7%.
Improved from $4.48 to $6.43 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Sector benchmark
#60 of 154 in Health CareTop 39% of 154This company $6.43 Sector average $10.35
▼
-37.9% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's revenue per share has grown for 9 consecutive years.
- In FY2025, revenue per share increased 10.5% year-over-year.
- Ranks #60 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.43 | +10.5% |
| FY2024 | $5.82 | +29.8% |
| FY2023 | $4.48 | +39.5% |
| FY2022 | $3.21 | +5.9% |
| FY2021 | $3.03 | +6.6% |
| FY2020 | $2.84 | +20.7% |
| FY2019 | $2.36 | +31.0% |
| FY2018 | $1.80 | +74.8% |
| FY2017 | $1.03 | +505.3% |
| FY2016 | $0.17 | +27784.3% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026